Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vaxdome Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The portfolio features a distinct examiner and a distinct art unit. FOLEY, SHANON A is the busiest examiner, currently managing 1 pending action. This focused prosecution profile means that the company's current patent efforts are centralized under a single examiner's review. Practitioners should evaluate the specific art unit's past behavior to anticipate potential hurdles in this biotechnology matter.
The presence of a pending office action indicates a streamlined prosecution environment. Because the portfolio is limited to a single distinct examiner and a single distinct art unit, there is no internal baseline for comparing examiner behavior or art unit efficiency within the company's own data. Success for Vaxdome Inc. depends on navigating the specific requirements of FOLEY, SHANON A. This concentration under a single point of review simplifies administrative tracking but increases the impact of any single procedural hurdle.
In the Biotechnology & Pharmaceuticals field, where examination can be highly technical, having a distinct art unit involved suggests a consistent application of subject matter standards. However, the reliance on a distinct examiner means that the company's patent trajectory is currently subject to a single perspective. Practitioners should focus on the historical allowance rates and common rejection types associated with the specific examiner to optimize their response strategy for the pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOLEY, SHANON A | 1 | 73.3% | +18.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18470999 | Neuraminidase-Inhibited Influenza Virus | FOLEY, SHANON A | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18470999 | Neuraminidase-Inhibited Influenza Virus | FOLEY, SHANON A | 1671 | §103 | Final Rejection | — | Pending | Sep 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVaxdome Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Shanon A Foley has the most, with 1 of Vaxdome Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
